Answers are grounded in this paper and cite their sources.
The last decade has seen significant advances in tuberculosis diagnostics and drug susceptibility testing (DST). During the same time period the prevalence of drug-resistant tuberculosis has increased and therefore it has become critical to understand DST for medications used to treat multidrug-resistant and extensively drug-resistant tuberculosis. This review describes recent molecular diagnostic advances for DST. Recommendations are provided for clinicians interpreting molecular DST and we describe potential opportunities for the field.
No takes yet. Share an insight, caveat, or question.
Heysell et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: